Cargando…

Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC

This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID‐19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudo, Masatoshi, Kurosaki, Masayuki, Ikeda, Masafumi, Aikata, Hiroshi, Hiraoka, Atsushi, Torimura, Takuji, Sakamoto, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Special Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361293/ https://www.ncbi.nlm.nih.gov/pubmed/32583525 http://dx.doi.org/10.1111/hepr.13541

Ejemplares similares

Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
por: Kudo, Masatoshi, et al.
Publicado: (2021)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2022)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
por: Yamashita, Tatsuya, et al.
Publicado: (2019)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
por: Torimura, Takuji, et al.
Publicado: (2021)

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2022)

Hepatocellular carcinoma: HCC
por: Blum, Hubert E.
Publicado: (2011)

Immunotherapy for hepatocellular carcinoma: current status and future perspectives
por: Okusaka, Takuji, et al.
Publicado: (2018)

Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then
por: Kawaguchi, Takumi, et al.
Publicado: (2020)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

4th International Kyoto Liver Cancer Symposium: Emerging Strategies to HCC. Kyoto, Japan, June 7–8, 2014: Abstracts
por: Kudo, Masatoshi
Publicado: (2014)

Human Hepatocellular Carcinoma (HCC)
por: Buonaguro, Luigi
Publicado: (2020)

Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach
por: Mazzaferro, Vincenzo
Publicado: (2016)

Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression
por: Kotsari, Maria, et al.
Publicado: (2023)

MRI in detection of hepatocellular carcinoma (HCC)
por: Digumarthy, Subba R, et al.
Publicado: (2005)

Emerging Therapies for Hepatocellular Carcinoma (HCC)
por: Chakraborty, Eesha, et al.
Publicado: (2022)

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
por: Bicer, Fuat, et al.
Publicado: (2023)

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis
por: Okusaka, Takuji, et al.
Publicado: (2023)

Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma
por: Hashida, Ryuki, et al.
Publicado: (2020)

Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2022)

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
por: Llovet, Josep M., et al.
Publicado: (2022)

Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma
por: Kawaguchi, Takumi, et al.
Publicado: (2020)

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Iwamoto, Hideki, et al.
Publicado: (2022)

Surgically treated diaphragmatic perforation after radiofrequency ablation for hepatocellular carcinoma
por: Nagasu, Sachiko, et al.
Publicado: (2017)

Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma
por: Kariyama, Kazuya, et al.
Publicado: (2019)

Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety‐Assessment Cohort
por: Doi, Toshihiko, et al.
Publicado: (2020)

Spleen and Liver
por: Torimura, Takuji
Publicado: (2016)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

Report of the 20th Nationwide follow‐up survey of primary liver cancer in Japan
por: Kudo, Masatoshi, et al.
Publicado: (2020)

First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
por: Shimose, Shigeo, et al.
Publicado: (2021)

Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response
por: Minami, Yasunori, et al.
Publicado: (2022)

Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
por: Kudo, Masatoshi
Publicado: (2018)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC)
por: Pazgan-Simon, Monika, et al.
Publicado: (2020)

NF-Y Overexpression in Liver Hepatocellular Carcinoma (HCC)
por: Bezzecchi, Eugenia, et al.
Publicado: (2020)

A Curious Case of Vanishing Hepatocellular Carcinoma (HCC)
por: Kwei-Nsoro, Robert, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a2kh6n7i99glm7f38cfij9e1c1